Journal of Materials Chemistry B

ROYAL SOCIETY OF CHEMISTRY

CORRECTION

Cite this: *J. Mater. Chem. B*, 2024, **12**, 275

Correction: Mitochondria-targeting nanozyme alleviating temporomandibular joint pain by inhibiting the TNFα/NF-κB/NEAT1 pathway

Qian Bai,[a] Yaoyao Zhou,[a] Xiaona Cui,[ab] Haichao Si,[e] Tingting Wu,[a] Abdul Nasir,[ac] Heng Ma,[ac] Junyue Xing,[d] Yingying Wang,[d] Xiaolei Cheng,[d] Xiaojun Liu,*[b] Shaoyan Qi,*[b] Zhisong Li[c] and Hao Tang*[d]

DOI: 10.1039/d3tb90183a

rsc.li/materials-b

Correction for 'Mitochondria-targeting nanozyme alleviating temporomandibular joint pain by inhibiting the TNFα/NF-κB/NEAT1 pathway' by Qian Bai *et al.*, *J. Mater. Chem. B*, 2023, **https://doi.org/10.1039/d3tb00929g**.

The authors regret the error in Fig. 6 due to a figure compilation error. The corrected Fig. 6 is shown below.

[a] *Medical Research Center, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China*
[b] *Department of Critical Care Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. E-mail: liuxiaojunzzu@163.com, qishaoyan1970@163.com*
[c] *Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China*
[d] *National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital of Zhengzhou University, Fuwai Central China Cardiovascular Hospital & Central China Branch of National Center for Cardiovascular Diseases, Zhengzhou, Henan, 451464, China. E-mail: tangpku_zzuhao@zzu.edu.cn*
[e] *Department of Anesthesiology, Nanyang Central Hospital, Nanyang, Henan, China*



Fig. 6 Intravenous Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated the TNFα/NF-κB/Neat1 pathways in a mouse TMD pain model. (A) Single i.v. Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated Neat1 in Sp5C in mouse TMD pain model after 3 d; $^{**}P < 0.01$; $^{****}P < 0.0001$, two-way ANOVA, $N = 18$. (B) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA injection downregulated p-p65 in Sp5C in mouse TMD pain model after 3 d; $^{****}P < 0.0001$ *vs.* CFA + vehicle; two-way ANOVA, $N = 39$. (C) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA/saline injection did not alter p65 expression in Sp5C after 3 d; $^{ns}P > 0.05$, $N = 27$. (D) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA injection counteracted the increase in p-p65 immunofluorescence intensity in Sp5C in mouse TMD pain model after 3 d (scale bar = 400 μm). (E) Statistical analysis of data in (D) $^{****}P < 0.0001$ *vs.* CFA + vehicle group, $N = 3$, two-way ANOVA. (F) Intra-Sp5C NF-κB injection in downregulated Neat1 in naive mice; $^{**}P < 0.01$ *vs.* Scramble control, $N = 5$; *t*-test. (G) Single i.v. Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated TNF-α in Sp5C in mouse TMD pain model after 3 d; $^{***}P < 0.001$ *vs.* CFA + vehicle, $N = 4$; two-way ANOVA.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

